Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.
Publication/Presentation Date
12-9-2020
Abstract
REVERSE is a randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial that evaluated the efficacy of a single intravitreal injection of rAAV2/2-
Volume
12
Issue
573
ISSN
1946-6242
Published In/Presented At
Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., La Morgia, C., Karanjia, R., Taiel, M., Blouin, L., Burguière, P., Smits, G., Chevalier, C., Masonson, H., Salermo, Y., Katz, B., … Sahel, J. A. (2020). Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Science translational medicine, 12(573), eaaz7423. https://doi.org/10.1126/scitranslmed.aaz7423
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
33298565
Department(s)
Administration and Leadership
Document Type
Article